Browse FMO1

Summary
SymbolFMO1
Nameflavin containing monooxygenase 1
Aliases FMO 1; Flavin-containing monooxygenase 1 (fetal liver); dimethylaniline oxidase 1; fetal hepatic flavin-cont ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Microsome membrane Single-pass membrane protein Endoplasmic reticulum membrane Single-pass membrane protein
Domain PF00743 Flavin-binding monooxygenase-like
Function

This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. Form I catalyzes the N-oxygenation of secondary and tertiary amines.

> Gene Ontology
 
Biological Process GO:0002237 response to molecule of bacterial origin
GO:0006732 coenzyme metabolic process
GO:0006733 oxidoreduction coenzyme metabolic process
GO:0006739 NADP metabolic process
GO:0006805 xenobiotic metabolic process
GO:0006970 response to osmotic stress
GO:0009404 toxin metabolic process
GO:0009410 response to xenobiotic stimulus
GO:0017144 drug metabolic process
GO:0019362 pyridine nucleotide metabolic process
GO:0019748 secondary metabolic process
GO:0032496 response to lipopolysaccharide
GO:0046496 nicotinamide nucleotide metabolic process
GO:0051186 cofactor metabolic process
GO:0070995 NADPH oxidation
GO:0071466 cellular response to xenobiotic stimulus
GO:0072524 pyridine-containing compound metabolic process
Molecular Function GO:0004497 monooxygenase activity
GO:0004499 N,N-dimethylaniline monooxygenase activity
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016709 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen
GO:0048037 cofactor binding
GO:0050660 flavin adenine dinucleotide binding
GO:0050661 NADP binding
GO:0050662 coenzyme binding
Cellular Component GO:0005788 endoplasmic reticulum lumen
> KEGG and Reactome Pathway
 
KEGG hsa00982 Drug metabolism - cytochrome P450
Reactome R-HSA-211859: Biological oxidations
R-HSA-217271: FMO oxidises nucleophiles
R-HSA-1430728: Metabolism
R-HSA-211945: Phase 1 - Functionalization of compounds
Summary
SymbolFMO1
Nameflavin containing monooxygenase 1
Aliases FMO 1; Flavin-containing monooxygenase 1 (fetal liver); dimethylaniline oxidase 1; fetal hepatic flavin-cont ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FMO1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFMO1
Nameflavin containing monooxygenase 1
Aliases FMO 1; Flavin-containing monooxygenase 1 (fetal liver); dimethylaniline oxidase 1; fetal hepatic flavin-cont ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FMO1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFMO1
Nameflavin containing monooxygenase 1
Aliases FMO 1; Flavin-containing monooxygenase 1 (fetal liver); dimethylaniline oxidase 1; fetal hepatic flavin-cont ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FMO1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3070.622
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6470.63
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.020.977
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1350.8
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3070.819
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0770.959
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4370.6
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.7670.525
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.210.875
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4130.854
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3820.902
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4290.209
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FMO1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.83.411.40.0746
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211733.3033.30.0108
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.5037.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.8030.80.0983
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFMO1
Nameflavin containing monooxygenase 1
Aliases FMO 1; Flavin-containing monooxygenase 1 (fetal liver); dimethylaniline oxidase 1; fetal hepatic flavin-cont ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FMO1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFMO1
Nameflavin containing monooxygenase 1
Aliases FMO 1; Flavin-containing monooxygenase 1 (fetal liver); dimethylaniline oxidase 1; fetal hepatic flavin-cont ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FMO1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FMO1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFMO1
Nameflavin containing monooxygenase 1
Aliases FMO 1; Flavin-containing monooxygenase 1 (fetal liver); dimethylaniline oxidase 1; fetal hepatic flavin-cont ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FMO1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFMO1
Nameflavin containing monooxygenase 1
Aliases FMO 1; Flavin-containing monooxygenase 1 (fetal liver); dimethylaniline oxidase 1; fetal hepatic flavin-cont ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FMO1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFMO1
Nameflavin containing monooxygenase 1
Aliases FMO 1; Flavin-containing monooxygenase 1 (fetal liver); dimethylaniline oxidase 1; fetal hepatic flavin-cont ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FMO1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFMO1
Nameflavin containing monooxygenase 1
Aliases FMO 1; Flavin-containing monooxygenase 1 (fetal liver); dimethylaniline oxidase 1; fetal hepatic flavin-cont ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FMO1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.